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Abstract
Background
Decisions concerning drug safety and efficacy are generally based on pivotal evidence
provided by clinical trials. Unfortunately, finding the relevant clinical trials is difficult and
their results are only available in text-based reports. Systematic reviews aim to provide a
comprehensive overview of the evidence in a specific area, but may not provide the data
required for decision making.
Methods
We review and analyze the existing information systems and standards for aggregate level
clinical trials information from the perspective of systematic review and evidence-based
decision making.
Results
The technology currently used has major shortcomings, which cause deficiencies in the
transfer, traceability and availability of clinical trials information. Specifically, data
available to decision makers is insufficiently structured, and consequently the decisions
cannot be properly traced back to the underlying evidence. Regulatory submission, trial
publication, trial registration, and systematic review produce unstructured datasets that are
insufficient for supporting evidence-based decision making.
Conclusions
The current situation is a hindrance to policy decision makers as it prevents fully transparent
decision making and the development of more advanced decision support systems.
Addressing the identified deficiencies would enable more efficient, informed, and
transparent evidence-based medical decision making.
Background
Motivation
Health care policy decision makers such as drug regulatory authorities, reimbursement policy
makers and guideline committees routinely evaluate the efficacy and safety of medicines, as
well as other factors such as costs. Clinical trials provide the pivotal evidence for drug
efficacy and safety. The ability to efficiently identify and make use of the results of existing
clinical trials is critical to evidence-based policy decision making.
Until recently, journal publications were the only generally available source of trial designs
and results. Thus, systematically reviewing the medical literature for the clinical trials that
address a specific topic is of central importance to evidence-based health care policy [1, 2].
This provides decision makers with a coherent overview of the current evidence, and also
helps to set the agenda for future clinical research [3, 4]. However, systematic reviewing is
currently not feasible for most decision makers, because it is time consuming and expensive.
Therefore, most decision makers will have to rely on published systematic reviews. However,
this is problematic because the review may not match the needs of the decision maker. Thus,
even when a relevant systematic review is available, there may be a need to go back to the
underlying trial data, especially for quantitative decision modeling. It may additionally be
necessary to update or extend the review, or to combine several of them. Doing so also
requires access to the underlying trial data, but these are not commonly reported. This is a
serious limitation to the efficiency of both evidence-based decision making and systematic
reviewing.
Thus, the quality of health care policy could be improved if systematic reviews could be
performed for whatever decision is currently at hand, ideally even on demand. This would
require enormous improvements to the manner in which clinical trials evidence is made
available. Although efforts to standardize the information systems for the management and
regulatory submission of clinical trials have been successful [5–7], this has not so far resulted
in similar improvements in the dissemination of clinical trial evidence. A comprehensive
overview of the various information systems that store and process clinical trials information
could identify the gaps in information transfer that limit the efficiency of systematic reviews
and consequently health care policy decision making.
Systematic review
The need to identify and summarize the evidence for decision makers is evident from the
sheer scale of the available information: PubMed alone indexes nearly 20 million publications
from over 5,500 journals, and this is only a selected subset of the biomedical literature [3].
Systematic review addresses this need and consists of three steps: literature screening, data
extraction, and reporting. In the first step, literature databases are searched, yielding a set of
potentially relevant publications. These are screened for suitability, which results in them
being included in, or excluded from, the review. Because literature searches are often
inaccurate, thousands of publications may need to be screened. Moreover, to ensure
comprehensiveness and avoid bias, multiple databases have to be searched [8] and multiple
publications of a single trial have to be identified as such. Once the relevant trials have been
identified and the corresponding reports retrieved, the data have to be extracted from the
reports. Finally, the collected data are summarized and combined (e.g. using meta-analysis),
and reported in a journal article or a technical report. Typically only this final product is made
available, even though making the results of the screening step and the extracted data available
would greatly enhance the efficiency of future systematic reviews and decision making. Thus,
to assess the efficiency of clinical trials results dissemination, systematic review should not be
ignored.
The difficulty of performing a systematic review also impacts the quality of systematic
reviews themselves: it leads to reviews that focus on a single treatment or a pair of treatments.
Consequently, for one particular therapeutic indication many competing reviews may be
available, that each provide only a small part of the overall picture [9]. This has led to
‘overviews of reviews’ or ‘umbrella reviews’ summarizing the results of several existing
reviews [10]. Umbrella reviews generally merely repeat the pooled summaries of treatment
effects from the original reviews, but it has been argued that they may lead to misleading and
inconsistent conclusions [9]. An approach based on the individual studies is therefore
preferable but labor-intensive if the data are not available in a structured format.
Scope and objectives
The aim of this paper is to identify opportunities to enhance the efficiency of systematic
review and evidence-based decision making, supported by a broad and useful overview of the
current state of the art in the transfer and availability of clinical trial evidence. To these ends,
we provide a critical overview of existing systems and standards that support the
dissemination of clinical trial results.
Because publicly available clinical trial results are nearly always aggregated (at the population
level) rather than reported per patient, and because most decision makers base their decisions
on such data, we limit the scope of this paper to systems and standards for the aggregate level.
Methods
We included academic publications and websites of manufacturers or standardization bodies
that describe information systems or standards that deal with the transfer and availability of
aggregate-level results of clinical trials. We also considered review articles and peer-reviewed
position papers related to such information systems.
We identified relevant publications through key word searches using Google, Google Scholar,
ISI Web of Science and PubMed (last searched May 2011). We also screened the reference
lists of included publications. In addition, through our participation in the Escher project of
the Dutch Top Institute Pharma (TI Pharma), we were able to engage in discussions with
many experts from the pharmaceutical industry, regulatory authorities, and academia.
Publications (both peer-reviewed articles and web pages published by companies or
standardization bodies) were screened for eligibility using titles and abstracts (if applicable).
Potentially relevant publications were read in full. If a peer-reviewed article and a web page
conveyed (nearly) identical information, only the peer-reviewed work was included.
Moreover, web pages were excluded if the source was not considered authoritative for the
subject matter. Included publications were summarized using keywords, and especially
important sections were highlighted for later reference. For each system and standard we
collected the context in which it is used, its purpose, its defining features, the types of data it
handles and/or produces, its connection to other systems or standards, and expected future
developments.
Results
In this section, we present the identified systems grouped according to the processes they
support. These are publication in the scientific literature, trial registration, systematic review,
and regulatory assessment. Figure 1 shows how these processes relate to each other, to the
operation of the trial itself, and to policy decision making. Subsequently, standards and data
models relevant to the dissemination of aggregate level results of clinical trials are discussed.
Figure 1 An overview of the processes dealing with clinical trials information and how
they relate to each other
Scientific literature
Pharmaceutical industry and other investigators may choose to summarize selected results of
clinical trials in manuscripts submitted to peer-reviewed scientific journals. A clinical trial
may result in any number of publications, from none to dozens. Unfortunately, such
publications frequently lack sufficient information to allow the reader to judge whether the
trial was rigorously conducted. The CONSORT statement [11, 12] aims to improve the
situation by providing guidance on the proper reporting of clinical trials. Nevertheless, trial
reporting is often still inadequate [13] and selective outcome reporting is common [14].
Reporting clinical trial results in text-based articles rather than properly structured data sets
makes computational processing of the results practically impossible [15]. Moreover,
although peer review is essential to guarantee the quality of such articles, publication in
scientific journals scatters the results throughout the scientific literature. The problem of
identifying and accessing clinical trial publications is addressed by abstract databases and
search engines, most notably PubMed (http://pubmed.com/), backed by the MEDLINE
database, and EMBASE (http://embase.com/), which maintains its own database; see Table 1
for their coverage. Both databases label abstracts using controlled vocabularies, allowing the
restriction of searches to clinical trials, controlled clinical trials, or systematic reviews of
clinical trials. However, not all abstracts might be labeled, which is why systematic reviewers
often broaden their search beyond these categories. PubMed’s Clinical Queries
(http://pubmed.com/clinical) provide optimized search strategies that have been empirically
validated for this use [16]. It might be useful in these cases to annotate which abstracts do not
belong to reports of clinical trials. Research is ongoing to improve the accuracy of search
results through text processing of abstracts [17] and to aid the screening process by ranking
the search results [18]. The Cochrane CENTRAL database of trial publications [19], kept
up-to-date by the non-commercial Cochrane Collaboration (http://www.cochrane.org/),
provides links to publications known to describe randomized controlled trials. It is quarterly
updated from MEDLINE, EMBASE, and databases of specialized Cochrane groups [20]
Records that are identified as clinical trials are reported back to MEDLINE.
When clinical trial results were only published in scientific journals, the decision whether to
publish the results was completely left to the investigator, which led to incomplete trial
reporting and publication bias [21]. For example, over half of the clinical trials that supported
successful new drug applications made to the Food and Drug Administration (FDA) had still
not been published 5 years after the medicines’ market approval [22]. This is a serious
problem that can lead to incorrect conclusions from a systematic review.
Trial registration
As early as 1986 the registration of trials in advance was proposed as a solution to publication
bias [23]. The trial bank concept proposes to take the registration of trials even further by
recording not only the existence of a trial, but also the study protocol (in advance) and the
results (after completion) in a “machine readable” way [15, 24]. For trial banks to be
successful, all trials must be entered in a way that conforms to a single machine-readable data
model [24,25]. The Global Trial Bank project was set up in 2005 to create a practically usable
Table 1 Coverage of abstract databases PubMed and EMBASE, and the Cochrane
Library.
all records since 2000 source
PubMed/MEDLINE (1 Jan 2011)
PubMed records 19,569,568 6,628,156 (1)
Identified clinical trial 457,378 171,025 (1)
Identified randomized controlled trial 293,963 156,496 (1)
Identified meta-analysis 25,723 21,146 (1)
Indexed journals 5,543 1,287 (2) 17 May 2011
EMBASE (17 May 2011)
EMBASE records  24 M (3)
EMBASE journals  7,500 (3)
Cochrane library (17 May 2011)
Clinical trials (CENTRAL) 645,086 286,418 (4) issue 2 of 4, Apr 2011
Cochrane reviews 4,621 4,621 (4) issue 5 of 12, May 2011
Other reviews 14,602 12,683 (4) issue 2 of 4, Apr 2011
All reviews (Cochrane + Other) 19,223 17,304
Cochrane protocols 2,020 2,020 (4) issue 5 of 12, May 2011
sources
1. http://www.nlm.nih.gov/bsd/licensee/baselinestats.html
2. http://www.nlm.nih.gov/tsd/serials/lji.html
3. http://embase.com/info/what-is-embase/coverage
4. http://thecochranelibrary.com/
trial bank [26], but in 2008 it was put on hold due to lack of funding [27].
The FDA Modernization Act of 1997 made the US the first country to make trial registration a
legal requirement. To implement this legislation, the ClinicalTrials.gov registry was launched
in February 2000 [28]. The initial installment focused on providing a record of trials for
enabling patient recruitment and investigator accountability. In 2004, both the World Health
Organization (WHO) and the International Committee of Medical Journal Editors (ICMJE)
released statements in support of the prospective registration of clinical trials. This policy has
been widely adopted and now assures that the existence of most recent trials is known [29].
Subsequently, various organizations, including the WHO, have called for a full disclosure of
the trial protocol (including amendments) and results [30–36]. In the US, recent
legislation [37] has required protocol registration since December 2007, basic results
reporting since September 2008, and Adverse Drug Events (ADEs) reporting since September
2009 [38]. Other governments with policies requiring prospective registration include the EU,
India, Argentina, Brasil, Israel and South Africa [39].
To register a trial in ClinicalTrials.gov [40], researchers enter summary protocol
information [41] when their studies are initiated, and subsequently create the results
section [42] when the data collection for at least one primary outcome measure is complete.
The ClinicalTrials.gov staff will review the results data after their submission. The data are
reported in a structured tabular format and some meta-data, such as units of measurement or
the use of standard vocabularies, can also be provided. Limited support for reporting
statistical analyses is offered; these analyses are tied to specific results tables. Study protocols
have long been available in XML format, and the retrieval of results in XML format was
added in December 2011 [43].
Other countries have set up their own registries. Since 2004, the European Medicines
Agency (EMA) has established clinical trial registration in accordance with the EU Directive
2001/20/EC through the EudraCT system. EudraCT was opened to the public only recently as
the EU Clinical Trials Register, on 22 March 2011 [44], and the records are being released in
a staggered fashion. Currently 17,102 [45] of over 28,150 registered trials [46] are available.
Another international registry is the Current Controlled Trials Ltd.’s ISRCTN registry, which
has been in operation since 1998 [47]. It provides a semi-structured textual representation of
the trial protocol, but no results. A number of countries have open national registries that
generally record information in a way similar to ISRCTN. All of these registries are less
sophisticated than ClinicalTrials.gov.
In order to unify trial registration world-wide, the WHO International Clinical Trials Registry
Platform (ICTRP) was established following the Ministerial Summit on Health Research in
November 2004. The goal of the ICTRP is to create “a network of international clinical trial
registries to ensure a single point of access and the unambiguous identification of trials” [48].
This network of trial registries, the WHO Registry Network, was formally launched in 2007.
In March 2012, 14 primary registries were listed on the ICTRP website (see Table 2). The
ICTRP also provides a search portal that collects and indexes some basic information on trials
from most of the primary registries and attempts to group trials that are registered in more than
one registry in the search results. The search portal provides a textual description of the trial
design as well as a link to the primary registry. Table 2 gives an overview of the WHO primary
registries and ClinicalTrials.gov, with the number of included studies and whether or not they
are indexed by the search portal. ClinicalTrials.gov is by far the largest registry, containing
more than 7 times the number of trials available in the second largest registry (EU Clinical
Trials Register), and 69% of all trials in the registries (not taking duplicates into account).
Moreover, ClinicalTrials.gov is the only registry that registers results. In January 2010 it had
published the results of 1,156 studies, which had increased to 5,436 studies by March 2012.
Although a decentralized system of federated registries (both national and multi-national)
seems cumbersome and may cause duplicate registration, there are important reasons why this
method is to be preferred to a centralized approach [49]: national registries, for example, are
in the position to ensure complete registration in their region of influence and are perfectly
aligned with the local political situation. As long as the different registries are sufficiently
interoperable, an overarching organization such as the ICTRP can aggregate their databases.
The increased transparency enabled by trial registration offers new opportunities for
evidence-based medicine and will likely lead to an increase in the number of systematic
reviews that are undertaken [50]. However, the current registries contain only text-based or
semi-structured information and lack a common coding system, for example for labeling
interventions. The amount of protocol information registered is often insufficient to judge the
validity of reported results and the problem of identifying all relevant studies has not yet been
Table 2 ClinicalTrials.gov and the 14 WHO primary registries, with the number of reg-
istered trials per 19 March 2012 (‘studies’), whether the register is indexed by the WHO
search portal (‘indexed’) and whether the registry also enables results publication (‘re-
sults’)
Register Studies Indexed Results
ClinicalTrials.gov (United States) 122,758 yes yes (5,436)
European Union Clinical Trials Register 17,102 no no
ISRCTN register (international) 10,465 yes no
Japan Primary Registries Network 8,329 yes no
Australian New Zealand Clinical Trials Registry 6,369 yes no
The Netherlands National Trial Register 3,187 yes no
Clinical Trials Registry - India 2,499 yes no
Iranian Registry of Clinical Trials 2,449 yes no
Chinese Clinical Trial Register 2,004 yes no
German Clinical Trials Register 831 yes no
Cuban Public Registry of Clinical Trials 392 yes no
South Korea Clinical Research Information Service 379 yes no
Brazilian Clinical Trials Registry 131 no no
Pan African Clinical Trial Registry 97 yes no
Sri Lanka Clinical Trials Registry 71 yes no
solved [29]. In addition, the publicly available information may be incomplete or even
“largely incomprehensible” [38]. The call for federated, open access, mandatory results
databases continues [32–36], and it is likely that the trend toward open and complete
registration of results will continue.
Systematic review
The process of systematic review produces data and meta-data that is potentially useful for
future reviewers and decision makers (see Background). The following assesses whether the
existing information systems enable the dissemination of this information.
The Cochrane Collaboration provides several databases to support reviewers. Besides the
CENTRAL database of clinical trials (see Section Scientific literature) the most relevant ones
are the Cochrane Database of Systematic Reviews, in which Cochrane reviews are
published [51], and the DARE database of other reviews. Table 1 provides statistics regarding
the scope of the library. In contrast to the traditional journal publications of systematic
reviews, which usually provide data in tables or figures, the Cochrane Reviews incorporate
descriptions and results of the original studies. However, the published dataset has many data
elements removed and the use of the data is restricted by license.
There are several software programs to aid in systematic review and meta-analysis, such as
Comprehensive Meta-Analysis, MetaWin, MetaStat and MetaAnalyst. Moreover, many
general-purpose statistical programs, such as SPSS Statistics, SAS Statistics, Stata, and R,
have meta-analysis functionality. In general, dedicated meta-analysis software will provide
easier data entry and management, while statistical programs will offer more powerful tools
for analysis. The Cochrane Collaboration also provides the Review Manager software for
performing systematic reviews (http://ims.cochrane.org/revman). Review Manager is unique
in that it provides not only data analysis and management features, but includes functionality
to write the full systematic review report. Indeed, the Review Manager file itself is submitted
to the Cochrane library for review and eventual publication. Unfortunately, all of these
systems lack sufficient meta-data to enable automated processing.
Finally, published systematic reviews are usually presented in a textual format without the
underlying dataset, making it difficult to perform additional analyses that may be required for
decision making. Thus, the inclusion of data on a new trial or new compound, as would be
required for regulatory decision making, is also impossible. In conclusion, systematic review
currently represents a missed opportunity to introduce additional structure to the available
clinical trials information.
Regulatory assessment
After a pharmaceutical company develops a drug, it compiles the evidence collected from the
discovery and development processes into a dossier that is submitted to the regulators who
decide upon its market authorization. Submissions to the EMA and the national medicines
boards in Europe are mainly text-based, containing aggregate-level results of clinical trials
based on the applicant’s statistical analysis. The FDA requests the submission of patient-level
data, which is unlikely to become publicly available and as such is out of scope for this paper.
The dossier forms the basis on which regulators assess the benefit-risk profile of a new drug.
Although the clinical trial results are pivotal in this assessment, the decision is only indirectly
based on them, as the decision making process is based on informal discussion between
experts. While the decision may still be of high quality, this informal framework does not
allow pharmaceutical companies or patients to discern how different pieces of the evidence
weigh in on it.
The EMA publishes the European Public Assessment Reports (EPARs) of all centrally
approved or refused medicines on its website. Note that this does not include all applications
submitted to the EMA, as they can be withdrawn before a decision is reached [52]. The EPAR
contains information on all trials, but is completely textual without a semantic structure.
Moreover, its information is directly derived from the submission by the applicant, while there
is no standardization concerning what information should be provided, or in which format.
Trials submitted to the EMA are required to be registered in EudraCT and will thus also be
made known to the public through the EU Clinical Trials Register.
Standards and data models
A common standard of how clinical trials are performed and how their results are presented
would make the process of systematic review more reliable and less laborous [15]. Some
progress has been made by ClinicalTrials.gov, which currently registers and displays
aggregate results. To do so, ClinicalTrials.gov has developed their own model, the Data
Element Definitions (DED) [41, 42]. This model allows the reporting of aggregated outcome
data and statistical analyses to some extent, but the information cannot be processed
automatically because most fields are free text. This also means that finding all trials that are
relevant to a specific patient condition is inaccurate, and thus requires overly broad search
terms [53]. This lack of standardization and interoperability among registries and other
databases should be addressed in the near future.
Several projects aim to enable general purpose re-use of clinical trials information, e.g. for
cross-study analyses. We identified three such projects. The first is the Biomedical Research
Integrated Domain Group (BRIDG) project, a collaboration between the Clinical Data
Interchange Standards Consortium (CDISC), Health Level 7 (HL7), the National Cancer
Institute (NCI) and the FDA that aims to bring together the common elements of their various
standards into a complete data model for clinical trials [54]. The BRIDG model is
implementation-independent in the sense that it specifies the problem domain, not a specific
solution. For example, unlike some other CDISC standards it does not specify the format in
which to submit data to the FDA. BRIDG is subdivided between the protocol representation,
study conduct, adverse event and regulatory perspectives. Unfortunately, a data analysis
perspective is currently missing as there is no adequate standard for the modelling of
statistical analyses. In short, the BRIDG model is accurate as regards the management of a
single clinical trial, but not as regards cross-study analysis [55]. For example, the study
population and eligibility criteria, outcomes and the measures used to assess outcomes do not
have a sufficiently deep semantic structure.
To enable cross-study analyses and efficiently finding relevant trials, the Human Studies
Database (HSDB) project aims to share fully machine understandable representations of study
design information between institutions [55]. HSDB is developing the Ontology of Clinical
Research (OCRe), which defines the concepts that should be accessible across the individual
institutions’ databases. At the time of writing, OCRe included a study design representation
derived from BRIDG [55], a study design typology [56], the ERGO formal machine readable
representation of eligibility criteria [53], and a model of study outcomes that separates the
phenomena of interest from the variables that encode them [55]. While OCRe is a promising
effort, its representation of study design is far from comprehensive, and it completely lacks a
model for trial results.
Finally, the Ontology Based eXtensible conceptual model (OBX) is another ontology for
representing clinical trials [57, 58]. Its aim is to make the results of immunology studies
available for data re-use and re-analysis. The OBX also incorporates study design
representation ideas from BRIDG and the ClinicalTrials.gov DED [57]. While it appears
successful in developing a broadly applicable data model for biomedical studies, and also
allows the inclusion of trial results, it would appear that OBX suffers from similar
shortcomings as regards the depth of modelling as BRIDG does.
All of the discussed models rely on an external coding system for their clinical content. Such
coding systems, known as controlled terminologies of clinical terms, are an important first
step in the application of information technology to medicine [59]. There are many controlled
terminologies for medicine, often developed for specific applications, but unfortunately there
is as yet no standardization of which ones should be used, and there is no accurate mapping
between them [60,61]. For example, in clinical research the Medical Dictionary for
Regulatory Activities (MedDRA) is used to code ADEs, while the healthcare area prefers the
Systematized Nomenclature of Medicine, Clinical Terms (SNOMED CT) dictionary. This
hinders the interoperability of the various information systems being used.
Discussion
Having reviewed the information systems and standards dealing with the information from
clinical trials, we will now summarize their deficiencies concerning the integration of clinical
trials information from different resources, discuss how the status quo could be improved and
identify directions for future research.
Identified deficiencies
Systems and standards oriented towards the management of single studies are relatively
mature, but this is not the case for cross-study analysis. There are no known large, successful,
and publicly available data warehouses, nor any standards that would enable cross-study
analyses of aggregate level results. Considerable effort is required to harmonize the current
clinical research standards. Important areas that require standardization are the representation
of statistical analyses and aggregate results, as well as complex semantic structures such as
patient eligibility criteria. None of the general purpose data models being developed are yet in
widespread use, and from the perspective of capturing the designs and results of clinical trials
in a reusable way, none of them are close to completion.
Although much effort is spent to publish the results of clinical trials, the current systems do
not facilitate optimal use of the information. The journals and abstract databases that publish
the trial results do not preserve the results’ structure and thus require manual data extraction.
Moreover, relevant articles are hard to identify and the retrieval of all available studies cannot
be guaranteed. Public registries are meant to improve the efficiency and reliability of the
identification of relevant studies, but the available data is not sufficiently structured to realize
this. Moreover, the systems that currently deal with clinical trials results are not interlinked
nor do they use interoperable standards. In short, there is not yet a comprehensive system of
structured machine-understandable databases that contains descriptions of the design,
execution, and summary-level results of individual trials. This situation hinders systematic
review and makes cross-study analyses and data-mining prohibitively difficult. Thus, current
infrastructure is focused on text-based reports of single studies, whereas efficient
evidence-based medicine requires the automated integration of multiple clinical trials from
different information resources.
Moreover, while systematic review collects and appraises the available evidence that is
relevant to a certain question, the results are published in an unstructured format. This makes
it hard to use the underlying data to inform evidence-based decisions, to verify the analyses, to
update the review or to perform a combined analysis of several reviews for an umbrella
review. The effort spent on literature screening and data extraction does not result in
availability of this information for future reviewers, leading to duplication of effort.
Therefore, the current systems are unnecessarily burdensome and do not sufficiently facilitate
reuse of the information. Figure 2 visualizes the current results dissemination process. Due to
these shortcomings, decisions are not explicitly linked to the underlying evidence, leading to a
lack of transparency, traceability, and reproducibility that is harmful for all stakeholders.
Figure 2 In the current system of clinical trials results dissemination, data are collected
in three separate systems (not including the organization that performs the trial)
Importantly, the perceived lack of transparency in regulatory decision making may erode
public trust in drug regulation and the pharmaceutical industry. More explicit quantitative
decision models would enable a more transparent and reproducible regulatory process, as well
as a clearer communication of the requirements to the industry. However, for most real-world
decisions it is currently too expensive to include all the evidence. This difficulty of accessing
existing data is not only relevant to regulators and the industry, but also to reimbursement
organizations, prescribing physicians and patients.
Proposed future situation
Now, we consider how these deficiencies might be addressed. Let us assume for a moment
that a comprehensive machine-understandable standard were available for the design and
aggregate level results of clinical trials. Then, it would be better for those submitting the data
if both regulators and registries used this format, rather than a number of disparate formats. In
addition, journal publications could easily be supplemented with data in this format.
Availability of a standard alone, however, is not enough to enable efficient access to the
evidence. The data sets also need to be collected and made available in such a way that
relevant clinical trials are easily identified. For this a collaborative (federated) system of
databases should be established to capture all clinical trials data. Some of the stakeholders
(e.g. regulators and registries) may require that data be submitted to a database that they
control so that they can ensure the integrity of the data. This is fine as long as (1) the
databases are interoperable and enable access to the information in the same format, (2) there
is a single point of access through which the different databases can be identified and located,
and (3) duplicate entries can be easily identified. It seems more likely for such a combination
of databases to emerge from the current registries than a single centralized system.
A comprehensive record of clinical trials in a machine-understandable format would make
systematic review and consequently evidence-based decision making much more efficient.
Decisions could then finally be explicitly linked to the underlying data (traceability). In
addition, this could also enable a new generation of decision support systems for health care
policy decision makers. The proposed future situation is visualized in Figure 3.
Figure 3 The alternative solution for clinical trials results dissemination proposed in this
paper: harmonization of the different systems to create a unified platform for
evidence-based decision making. Regulatory assessment has been merged into general
policy decision making
However, a suitable general-purpose data model is not likely to become available in the near
future. Further, the usefulness of any data model should be demonstrated to the industry and
other stakeholders before putting it into practice. We argue that the requirements for a general
purpose data model for cross-study analysis and decision making are not sufficiently well
known at the moment. Therefore, analysis tools and decision support systems that ensure data
extraction done for the analysis can be shared with other researchers should be developed first,
to illuminate these requirements.
Research directions
In order to attain the desired future system for aggregate-level clinical trial results
dissemination, we identify concrete research directions for medical informatics, decision
making and statistics researchers. Progress on each of these topics can be made in parallel.
 Computer-supported decision models for policy decision making based on clinical trials
– to enable a direct and explicit link between the decision and the supporting evidence
in drug regulation, reimbursement policy and guideline formulation
 Development of a platform to share structured systematic review data sets
 Discovery or creation of incentives for systematic reviewers to share the results of
literature screening and data extraction
 Identification of the core data elements and modeling that are needed to increase the
accuracy of literature searches
 Automated tagging and data extraction to facilitate transition to more structured data
sets
 Development of search tools to integrate querying of abstract databases and registries
 Development of methods to identify duplicate trial publications and registrations
 Development of a comprehensive data model for clinical trials and their aggregate level
results
Limitations
As with any review paper, there is a risk that relevant publications have not been identified,
either because the search terms were not broad enough, or because relevant studies were not
identified as such based on their title and abstract. We acknowledge that the broad scope of
this particular review increases that risk.
The nature of the collected information necessitates a qualitative synthesis, and the identified
deficiencies are at least partially subjective. The future that we propose is based on the
premise that a standard for aggregate clinical trial data will become available. Unfortunately,
it is unclear how and when this could be realized. Finally, the list of proposed research
directions is sure to be incomplete, and we hope the present paper will ignite discussions on
this topic.
Conclusions
We reviewed the existing systems and standards dealing with aggregate level results of clinical
trials. The transfer of evidence to scientific journals, public registries, and regulators is a
largely ad hoc and text-based affair. In part, this is because there are currently no data
standards that enable cross-study analyses. We have argued that the lack of a standardized,
federated system for results dissemination leads to gaps in the transfer and availability of
evidence to the relevant decision makers. As long as such a system does not exist, systematic
review will remain an incredibly inefficient ad-hoc process, and evidence-based decision
making will remain unnecessarily difficult. We believe that these difficulties lead to a lack of
transparency in health care policy decision making, which threatens public trust in the
decision makers.
In the future, results registries and regulatory systems should be harmonized and federated to
create a system of databases that forms the core of a more automated and efficient process of
systematic review and evidence-based decision making. In addition, systematic reviews are
currently a missed opportunity to introduce additional structure to the domain of clinical trials
information, which should be addressed by more complete dissemination of their results.
Although this vision is still far from realized, current trends seem to support this direction.
Future work should not only focus on developing the ‘ideal’ data model for all of clinical
research (justly called a monumental task) but start by creating useful tools to decision makers
and systematic reviewers. Availability of such tools will lead to increased demand for an
accessible evidence base and to a better understanding of its requirements.
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